[1. Alzheimer A. Uber eine eigenartige Erkrankung der Hirnrinde. Allgemeine Zeitschrift fur Psychiatrie und Psychish-Gerichtliche Medizin 1907;64:146-18.]Search in Google Scholar
[2. Alzheimer’s disease facts and figures. Alzheimer’s Dement. 2018;14:367–429.10.1016/j.jalz.2018.02.001]Search in Google Scholar
[3. Tanzi RE. The genetics of Alzheimer’s disease. Cold Spring Harb Perspect Med. 2012; 2(10):pii:a006296. doi: 10.1101/cshperspect. a006296]Search in Google Scholar
[4. van der Flier WM, Pijnenburg YAL, Fox NC, Scheltens P. Early-onset versus late-onset Alzheimer’s disease: the case of the missing APOE epsilon 4 allele”, Lancet Neurol. 2011;10(3):280-8.]Search in Google Scholar
[5. Wisniewski T, Dowjat WK, Buxbaum JD, Khorkova O, Efthimiopoulos S, Kulczycki J, Lojkowska W, Wegiel J, Wisniewski HM, Frangione B. A novel polish presenilin-1 mutation (P117L) is associated with familial Alzheimer’s disease and leads to death as early as the age of 28 years. NeuroReport. 1998;9(2):217–21.10.1097/00001756-199801260-00008]Search in Google Scholar
[6. Levy-Lahad E, Wijsman EM, Nemens E, Anderson L, Goddard KA, Weber JL, Bird TD, Schellenberg GD. A familial Alzheimer’s disease locus on chromosome 1. Science. 1995;269(5226):970-3.10.1126/science.7638621]Search in Google Scholar
[7. St George-Hyslop P, Haines J, Rogaev E, Mortilla M, Vaula G, Pericak-Vance M, Foncin JF, Montesi M, Bruni A, Sorbi S. Genetic evidence for a novel familial Alzheimer’s disease locus on chromosome 14, Nat Genet. 1992;2(4),330-4.]Search in Google Scholar
[8. Lambert JC, Amouyel P. Genetics of Alzheimer’s disease: new evidences for an old hypothesis? Curr Opin Genet Dev. 2011;21:295–301.]Search in Google Scholar
[9. Selkoe DJ. The molecular pathology of Alzheimer’s disease. Neuron. 1991;6:487–98.10.1016/0896-6273(91)90052-2]Search in Google Scholar
[10. 10. Frost B, Jacks RL, Diamond MI. Propagation of tau misfolding from the outside to the inside of a cell. J Biol Chem. 2009;284:12845–52.10.1074/jbc.M808759200]Search in Google Scholar
[11. Butterfield DA, Halliwell B. Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease. Nat Rev Neurosci. 2019;20:148–60.10.1038/s41583-019-0132-6]Search in Google Scholar
[12. Hardy J, Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer’s disease. Trends Pharmacol Sci. 1991;12:383–8.10.1016/0165-6147(91)90609-V]Search in Google Scholar
[13. Fan L, Mao C, Hu X, Zhang S, Yang Z, Hu Z, Sun H, Fan Y, Dong Y, Yang J, Shi C, Xu Y. New Insights Into the Pathogenesis of Alzheimer’s Disease. Front Neurol. 2020;10:1312.doi: 10.3389/fneur.2019.01312.10.3389/fneur.2019.01312696506731998208]Search in Google Scholar
[14. Coronel R, Bernabeu-Zornoza A, Palmer C, Muniz-Moreno M, Zambrano A, Cano E, Liste I. Role of amyloid precursor protein (APP) and its derivatives in the biology and cell fate specification of neural stem cells. Mol Neurobiol. 2018;55:7107–17.10.1007/s12035-018-0914-229383688]Search in Google Scholar
[15. Wiltfang J, Esselmann H, Bibl M, Smirnov A, Otto M, Paul S, Schmidt B, Klafki HW, Maler M, Dyrks T, Bienert M, Beyermann M, Rüther E, Kornhuber J. Highly conserved and disease-specific patterns of carboxyterminally truncated Abeta peptides 1-37/38/39 in addition to 1-40/42 in Alzheimer’s disease and in patients with chronic neuroinflammation. J Neurochem. 2002;81:481-96.10.1046/j.1471-4159.2002.00818.x12065657]Search in Google Scholar
[16. Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y. Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). Neuron. 1994;13:45-53.10.1016/0896-6273(94)90458-8]Search in Google Scholar
[17. Suzuki N, Iwatsubo T, Odaka A, Ishibashi Y, Kitada C, Ihara Y. High tissue content of soluble beta 1-40 is linked to cerebral amyloid angiopathy. Am J Pathol. 1994; 145:452-60.]Search in Google Scholar
[18. Lustbader JW, Cirilli M, Lin C, Xu HW, Takuma K, Wang N, Caspersen C, Chen X, Pollak S, Chaney M, Trinchese F, Liu S, Gunn-Moore F, Lue LF, Walker DG, Kuppusamy P, Zewier ZL, Arancio O, Stern D, Yan SS, Wu H. ABAD directly links Abeta to mitochondrial toxicity in Alzheimer’s disease. Science. 2004;304:448–52.10.1126/science.1091230]Search in Google Scholar
[19. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science. 2002;297:353–6.10.1126/science.1072994]Search in Google Scholar
[20. Hunt DL, Castillo PE. Synaptic plasticity of NMDA receptors: mechanisms and functional implications. Curr Opin Neurobiol. 2012;22:496–508.10.1016/j.conb.2012.01.007]Search in Google Scholar
[21. Vergara C, Houben S, Suain V, Yilmaz Z, De Decker R, Vanden Dries V, Boom A, Mansour S, Leroy K, Ando K, Brion JP. Amyloid-β pathology enhances pathological fibrillary tau seeding induced by Alzheimer PHF in vivo. Acta Neuropathol. 2019;137:397–412.10.1007/s00401-018-1953-5]Search in Google Scholar
[22. Lewis J, Dickson DW, Lin WL, Chisholm L, Corral A, Jones G, Yen SH, Sahara N, Skipper L, Yager D, Eckman C, Hardy J, Hutton M, McGowan E. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science. 2001;293:1487-91.10.1126/science.1058189]Search in Google Scholar
[23. Götz J, Chen F, van Dorpe J, Nitsch RM. Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science. 2001;293:1491-5.10.1126/science.1062097]Search in Google Scholar
[24. Ferreira ST, Klein WL. The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease. Neurobiol Learn Mem. 2011;96:529–43.10.1016/j.nlm.2011.08.003]Search in Google Scholar
[25. Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L, Beach T, Kurth JH, Rydel RE, Rogers J. Soluble amyloid beta peptide conentration as a predictor of synaptic change in Alzheimer’s disease. Am J Pathol. 1999;155:853-62.10.1016/S0002-9440(10)65184-X]Search in Google Scholar
[26. Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, Katzman R. Physical basis of cognitive alterations in Alzheimer’s disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991;30:572-80.10.1002/ana.4103004101789684]Search in Google Scholar
[27. Johansson A-S. Amyloid-β Protofibril Formation and Neurotoxicity. Implications for Alzheimer’s Disease. Acta Universitatis Upsaliensis, Uppsala, 2007. ISBN 978-91-554-6827-9.]Search in Google Scholar
[28. Wischik CM, Novak M, Edwards PC, Klug A, Tichelaar W, Crowther RA. Structural characterization of the core of the paired helical filament of Alzheimer disease. Proc Natl Acad Sci USA. 1988;85:4884–8.10.1073/pnas.85.13.4884]Search in Google Scholar
[29. Regan P, Whitcomb DJ, Cho K. Physiological and pathophysiological implications of synaptic tau. Neuroscientist. 2017;23:137–51.10.1177/1073858416633439]Search in Google Scholar
[30. Jean DC, Baas PW. It cuts two ways: microtubule loss during Alzheimer disease. Embo J. 2013;32:2900-2.10.1038/emboj.2013.219]Search in Google Scholar
[31. Kimura T, Whitcomb DJ, Jo J, Regan P, Piers T, Heo S, Brown C, Hashikawa T, Murayama M, Seok H, Sotiropoulos I, Kim E, Collingridge GL, Takashima A, Cho K. Microtubule-associated protein tau is essential for long-term depression in the hippocampus. Philos Trans R Soc Lond B Biol Sci. 2014;369:20130144.10.1098/rstb.2013.0144]Search in Google Scholar
[32. Jara C, Aranguiz A, Cerpa W, Tapia-Rojas C, Quintanilla RA. Genetic ablation of tau improves mitochondrial function and cognitive abilities in the hippocampus. Redox Biol. 2018;18:279-94.10.1016/j.redox.2018.07.010]Search in Google Scholar
[33. Lace GL, Wharton SB, Ince PG. A brief history of tau: the evolving view of the microtubule-associated protein tau in neurodegenerative diseases. Clin Neuropathol. 2007;26(2):43-58.10.5414/NPP26043]Search in Google Scholar
[34. Kril JJ, Patel S, Harding AJ, Halliday GM. Neuron loss from Alzheimer’s disease exceeds extracellular neurofibrillary tangle formation. Acta Neuropathol. (Berlin) 2002;103:370-376.]Search in Google Scholar
[35. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. (Berlin) 1991;82:239-59.]Search in Google Scholar
[36. Mann DMA. The neuropathology of Alzheimer’s disease: a review with pathogenetic, ætiological and therapeutic considerations. Mech Age Dev. 1985;31:213-55.10.1016/0047-6374(85)90092-2]Search in Google Scholar
[37. Hyman BT, van Hoesen GW, Damasio AR, Barnes CL. Alzheimer’s disease: cell-specific pathology isolates the hippocampal formation. Science. 1984;225:1168–70.10.1126/science.6474172]Search in Google Scholar
[38. Greenamyre JT, Young AB. Excitatory amino acids and Alzheimer’s disease. Neurobiol Aging. 1989;10:593-602.10.1016/0197-4580(89)90143-7]Search in Google Scholar
[39. Albin RL, Greenamyre JT. Alternative excitotoxic hypotheses. Neurology. 1992;42:733-8.10.1212/WNL.42.4.733]Search in Google Scholar
[40. Choi DW. Excitotoxic cell death. J Neurobiol. 1992;23:1261-76.10.1002/neu.480230915]Search in Google Scholar
[41. Walton HS, Dodd PR. Glutamate-glutamine cycling in Alzheimer’s disease. Neurochem Int. 2007;50:1052-66.10.1016/j.neuint.2006.10.007]Search in Google Scholar
[42. Kok E. Alzheimer’s Disease Neuropathology and Inflammation. A genetic and immunohistochemical study. Academic dissertation, University of Tampere, 2011.]Search in Google Scholar
[43. Hallberg M. Neuropeptides: metabolism to bioactive fragments and the pharmacology of their receptors. Med Res Rev. 2015;35(3):464-519.10.1002/med.21323]Search in Google Scholar
[44. Hallberg M, Nyberg F. Neuropeptide conversion to bioactive fragments - an important pathway in neuromodulation. Curr Protein Pept. 2003;4(1):31-44.10.2174/1389203033380313]Search in Google Scholar
[45. Chen XY, Du YF, Chen L. Neuropeptides Exert Neuroprotective Effects in Alzheimer’s Disease. Front Mol Neurosci. 2019;11:493.10.3389/fnmol.2018.00493]Search in Google Scholar
[46. Saito T, Takaki Y, Iwata N, Trojanowski J, Saido TC. Alzheimer’s disease, neuropeptides, neuropeptidase, and amyloid-beta peptide metabolism. Sci Aging Knowledge Environ. 2003;2003(3):PE1.10.1126/sageke.2003.3.pe1]Search in Google Scholar
[47. Van Dam D, Van Dijck A, Janssen L, De Deyn PP. Neuropeptides in Alzheimer’s disease: from pathophysiological mechanisms to therapeutic opportunities. Curr Alzheimer Res. 2013;10(5):449-68.10.2174/1567205011310050001]Search in Google Scholar
[48. Petrella C, Di Certo MG, Barbato C, Gabanella F, Ralli M, Greco A, Possenti R, Severini C. Neuropeptides in Alzheimer’s Disease: An Update. Curr Alzheimer Res. 2019;16(6):544-58.10.2174/1567205016666190503152555]Search in Google Scholar
[49. Fliers E, Swaab DF. Neuropeptide changes in aging and Alzheimer’s disease. Prog Brain Res. 1986;70:141-52.10.1016/S0079-6123(08)64302-2]Search in Google Scholar
[50. Hayashi M, Yamashita A, Shimizu K. Somatostatin and brain-derived neurotrophic factor mRNA expression in the primate brain: decreased levels of mRNAs during aging. Brain Res. 1997;749:283-9.10.1016/S0006-8993(96)01317-0]Search in Google Scholar
[51. Takagi H, Shiomi H, Ueda H, Amano H. Morphine-like analgesia by a new dipeptide, L-tyrosyl-L-arginine (Kyotorphin) and its analogue. Eur J Pharmacol. 1979;55(1):109-11.10.1016/0014-2999(79)90154-7]Search in Google Scholar
[52. Nishimura K, Kaya K, Hazato T, Ueda H, Satoh M, Takagi H. Kyotorphin like substance in human cerebrospinal fluid of patients with persistent pain. Masui 1991;40(11):1686-90.]Search in Google Scholar
[53. Shiomi H, Ueda H, Takagi H. Isolation and identification of an analgesic opioid dipeptide kyotorphin (Tyr-Arg) from bovine brain. Neuropharmacol 1981;20(7):633-8.10.1016/0028-3908(81)90109-X]Search in Google Scholar
[54. Shiomi H, Kuraishi Y, Ueda H, Harada Y, Amano J, Takagi H. Mechanism of kyotorhin-induced release of met-enkephalin from guinea pig striatum and spinal cord. Brain Res. 1981;221:161-9.10.1016/0006-8993(81)91070-2]Search in Google Scholar
[55. Ueda H, Yoshihara Y, Fukushima N, Shiomi H, Nakamura A, Takagi H. Kyotorphin (tyrosinearginine) synthetase in rat brain synaptosomes. J Biol Chem. 1987;262(17):8165-73.10.1016/S0021-9258(18)47544-8]Search in Google Scholar
[56. Yoshihara Y, Ueda H, Fujii N, Shide A, Yajima H, Satoh M. Purification of a novel type of calcium-activated neutral protease from rat brain. Possible involvement in production of the neuropeptide kyotorphin from calpastatin fragments. J Biol Chem. 1990;265(10):5809-15.10.1016/S0021-9258(19)39435-9]Search in Google Scholar
[57. Ueda H, Miyamae T, Fukushima N, Watanabe S, Misu Y. Evidence for a metabostatic opioid kappa-receptor inhibiting pertussis toxin-sensitive metabotropic glutamate receptor-currents in Xenopus oocytes. FEBS Lett. 1995;375(3):201-5.10.1016/0014-5793(95)01204-R]Search in Google Scholar
[58. Ueda H, Miyamae T, Hayashi C, Watanabe S, Fukushima N, Sasaki Y, Iwamura T, Misu Y. Protein kinase C involvement in homologous desensitization of delta-opioid receptor coupled to Gi1-phospholipase C activation in Xenopus oocytes. J Neurosci. 1995;15(11):7485-99.10.1523/JNEUROSCI.15-11-07485.1995]Search in Google Scholar
[59. Ueda H, Yoshihara Y, Takagi H. A putative met-enkephalin releaser, kyotorphin enhances intracellular Ca2+ in the synaptosomes. Biochem Biophys Res Commun. 1986;137(2):897-902.10.1016/0006-291X(86)91164-2]Search in Google Scholar
[60. Ueda H, Shiomi H., Takagi H. Regional distribution of a novel analgesic dipeptide kyotorphin (Tyr-Arg) in the rat brain and spinal cord. Brain Res. 1980;198(2):460-4.10.1016/0006-8993(80)90761-1]Search in Google Scholar
[61. Ribeiro MM, Pinto AR, Domingues MM, Serrano I, Heras M, Bardaji ER, Tavares I, Castanho MA. Chemical conjugation of the neuropeptide kyotorphin and ibuprofen enhances brain targeting and analgesia. Mol Pharm. 2011;8(5):1929-40.10.1021/mp200301621830793]Search in Google Scholar
[62. Ribeiro MM, Pinto A, Pinto M, Heras M, Martins I, Correia A, Bardaji E, Tavares I, Castanho M. Inhibition of nociceptive responses after systemic administration of amidated kyotorphin. Br J Pharmacol. 2011;163(5):964-73.10.1111/j.1476-5381.2011.01290.x]Search in Google Scholar
[63. Fujita T, Kishida T, Okada N, Ganapathy V, Leibach FH, Yamamoto A. Interaction of kyotorphin and brain peptide transporter in synaptosomes prepared from rat cerebellum: implication of high affinity type H+/peptide transporter PEPT2 mediated transport system. Neurosci Lett. 1999;271(2):117-20.10.1016/S0304-3940(99)00540-6]Search in Google Scholar
[64. Fujita T, Kishida T, Wada M, Okada N, Yamamoto A, Leibach FH, Ganapathy V. Functional characterization of brain peptide transporter in rat cerebral cortex: identification of the high-affinity type H+/peptide transporter PEPT2. Brain Res. 2004;997(1):52-61.10.1016/j.brainres.2003.10.049]Search in Google Scholar
[65. Dieck ST, Heuer H, Ehrchen J, Otto C, Bauer K. The peptide transporter PEPT2 is expressed in rat brain and mediates the accumulation of the fluorescent dipeptide derivative h-Ala-Lys-Nq-AMCA in astrocytes, glia. 1999;25:10-20.]Search in Google Scholar
[66. Berger U.V., M.A. Hediger, Distribution of peptide transporter PEPT2 mRNA in the rat nervous system, Anat Embryol. 1999;199:439-49.]Search in Google Scholar
[67. Nazarenko IV, Zvrushchenko MSh, Volkov AV, Kamenskii AA, Zaganshin RKh. Functional-morphologic evaluation of the effect of the regulatory peptide kyotorphin on the status of the CNS in the post-resuscitation period. Patol Fiziol Eksp Ter. 1999; (2):31-3.]Search in Google Scholar
[68. Dzambazova E, Bocheva A, Landzhov B, Bozhilova-Pastirova A. Effects of kyotorphin on NADPH-d reactive neurons in rats after cold stress. Compt Rend Acad Bulg Sci. 2008;61(5):661-6.]Search in Google Scholar
[69. Dzambazova E, Bocheva A, Landzhov B, Bozhilova-Pastirova A. Stress-induced nitric oxide activity in rat’s paraventricular nucleus was affected by kyotorphin and its synthetic analogue. Coll Symp Ser. 2009;11:28-30.10.1135/css200911028]Search in Google Scholar
[70. Dzambazova E, Landzhov B, Bocheva A, Bozhilova-Pastirova A. Effects of kyotorphin on NADPH-d reactive neurons in rat’s cerebral cortex after acute immobilization stress. Compt Rend Bulg Acad Sci. 2011; 64(12):1779-84.]Search in Google Scholar
[71. Santalova IM, Mavlyutov TA, Moshkov DA. Morphofunctional changes in Mauthner neurons during exposure to the neuropeptide kyotorphin. Neu rosci Behav Physiol. 2004;34:327-32.10.1023/B:NEAB.0000018741.79726.70]Search in Google Scholar
[72. Dzhambazova E, Bocheva A. The unique brain dipeptide kyotorphin - from discovery to nowadays. J Biomed Clin Res. 2010;3(1):3-11.]Search in Google Scholar
[73. Gorenkova NA, Nazarenko IV, Samorukova IV, Avrushchenko M, Volkov AV. Therapy of postresuscitation behavioral disorders with mexidol and kyotorphin. Anesteziol Reanimatol. 2002;6:63-66.]Search in Google Scholar
[74. Godlevsky LS, Shandra AA, Mikhaleva II, Vastyanov RS, Mazarati AM. Seizure-protecting effects of kyotorphin and related peptides in an animal model of epilepsy. Brain Res Bull. 1995;37(3):223-6.10.1016/0361-9230(94)00274-5]Search in Google Scholar
[75. Shandra AA. Role of neuropeptides in the mechanisms of chronic epileptization of the brain. Neurophysiology. 1999;31:75-8.10.1007/BF02515038]Search in Google Scholar
[76. Emelianova T, Usenko A, Ushakov V, Kononova L, Michaleva I. Effects of kyotorphin and neokyotorphin on thermoregulation in rats at different temperatures. In: Kolaeva S, Popova N, Solomonov N, Wahg L, Eds. Ecologo-physiological characteristics of natural hypometabolic states. Puschino: ONTI SGBK, 1992. p. 132–7.]Search in Google Scholar
[77. Ignat’ev DA, Vorob’ev VV, Ziganshin RKh. Effects of a number of short peptides isolated from the brain of the hibernating ground squirrel on the EEG and behavior in rats. Neurosci Behav Physiol. 1998;28(2):158-66.10.1007/BF024619629604218]Search in Google Scholar
[78. Dzambazova-Maximova E., A. Bocheva, Hr. Nocheva. Is kyotorphin an antiopioid peptide. Bulg Chem Commun. 2006;38(1):36-41.]Search in Google Scholar
[79. Dzhambazova E. Possible anti-stressor effects of kyotorphin and its optical isomer. Pharmacologia, 6(8), 413-420, 2015.10.5567/pharmacologia.2015.413.420]Search in Google Scholar
[80. Santos SM, Garcia-Nimo L, Sá Santos S, Tavares I, Cocho JA, Castanho MA. Neuropeptide Kyotorphin (Tyrosyl-Arginine) has decreased levels in the cerebro-spinal fluid of Alzheimer’s Disease patients: Potential diagnostic and pharmacological implications. Front Aging Neurosci. 2013;5:68. doi: 10.3389/fnagi.2013.00068.10.3389/fnagi.2013.00068381256424198785]Search in Google Scholar
[81. Sulkava R, Erkinjuntti T, Laatikainen T. CSF beta-endorphin and beta-lipotropin in Alzheimer’s disease and multiinfarct dementia. Neurology. 1985;35(7):1057-8.10.1212/WNL.35.7.1057]Search in Google Scholar
[82. Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol. 2010:6:131-44.10.1038/nrneurol.2010.4]Search in Google Scholar
[83. Sabuncu MR, Desikan RS, Sepulcre J, Yeo BT, Liu H, Schmansky NJ, Reuter M, Weiner MW, Buckner RL, Sperling RA, Fischl B. The dynamics of cortical and hippocampal atrophy in Alzheimer disease. Arch Neurol. 2011;68:1040-8.10.1001/archneurol.2011.167]Search in Google Scholar
[84. Borsook D. Neurological diseases and pain. Brain. 2012;135:320-44.10.1093/brain/awr271]Search in Google Scholar
[85. Farrell MJ, Katz B, Helme RD. The impact of dementia on the pain experience. Pain. 1996;67(1):7-15.10.1016/0304-3959(96)03041-2]Search in Google Scholar
[86. Benedetti F, Vighetti S, Ricco C, Lagna E, Bergamasco B, Pinessi L, Rainero I. Pain threshold and tolerance in Alzheimer’s disease. Pain. 1999;80(1-2):377-82.10.1016/S0304-3959(98)00228-0]Search in Google Scholar
[87. Santos S, Castanho M. The use of visual analog scales to compare pain between patients with Alzheimer’s Disease and patients without any known neurodegenerative disease and their caregivers. Am J Alzheimers Dis Other Demen. 2014;29(4):320-5.10.1177/153331751351704624370623]Search in Google Scholar
[88. Ayoub M, Scheidegger D. Peptide drugs, overcoming the challenges, a growing business. Chem Today. 2006;24:46-8.]Search in Google Scholar
[89. Marx V. Watching peptide drugs grow up. Chem Eng News. 2005;83(11):17-24.10.1021/cen-v083n011.p017]Search in Google Scholar
[90. Sá Santos S, Santos SM, Pinto AR, Ramu VG, Heras M, Bardaji E, Tavares I, Castanho MA. Amidated and ibuprofen-conjugated kyotorphins promote neuronal rescue and memory recovery in cerebral hypoperfusion dementia model. Front Aging Neurosci. 2016;8:1. doi: 10.3389/fnagi.2016.0000110.3389/fnagi.2016.00001472679926858637]Search in Google Scholar
[91. Conceição K, Magalhães PR, Campos SR, Domingues MM, Ramu VG, Michalek M, Bertani P, Baptista AM, Heras M, Bardaji ER, Bechinger B, Ferreira ML, Castanho MA. The anti-inflammatory action of analgesic kyotorphin neuropeptide derivatives: insights of a lipid-mediated mechanism. Amino Acids. 2016;48(1):307-18.10.1007/s00726-015-2088-926347373]Search in Google Scholar
[92. Dehghan-Shasaltaneh M, Naghdi N, Choopani S, Alizadeh L, Bolouri B, Masoudi-Nejad A, Riazi GH. Determination of the Best Concentration of Streptozotocin to Create a Diabetic Brain Using Histological Techniques. J Mol Neurosci. 2016;59(1):24-35.10.1007/s12031-015-0702-7]Search in Google Scholar
[93. Angelova H., D. Pechlivanova, E. Dzhambazova, B. Landzhov. Effects of kyotorphin on the early behavioral and histological changes induced by an experimental model of Alzheimer’s disease in rats. Compt Rend Acad Bulg Sci. 2018;71(3):424-30.]Search in Google Scholar
[94. Angelova H, Pechlivanova D, Krumova E, Miteva-Staleva J, Kostadinova N, Dzhambazova E, Landzhov B. Moderate protective effect of kyotorphin against the late consequences of intracerebroventricular streptozotocin model of Alzheimer’s disease. Amino Acids. 2019;51(9):1-13.10.1007/s00726-019-02784-5]Search in Google Scholar
[95. Arima T, Kitamura Y, Nishiya T, Takagi H, Nomura Y. Kyotorphin (L-tyrosyl-L-arginine) as a possible substrate for inducible nitric oxide synthase in rat glial cells. Neurosci Lett. 1996;212(1):1-4.10.1016/0304-3940(96)12758-0]Search in Google Scholar
[96. Arima T, Kitamura Y, Nishiya T, Taniguchi T, Takagi H, Nomura Y. Effects of kyotorphin (L-tyrosyl-L-arginine) ON[3H]NG-nitro-L-arginine binding to neuronal nitric oxide synthase in rat brain. Neurochem Int. 1997;30(6):605-11.10.1016/S0197-0186(96)00098-8]Search in Google Scholar
[97. de la Torre JC, Stefano GB. Evidence that Alzheimer’s disease is a microvascular disorder: the role of constitutive nitric oxide. Brain Res Brain Res Rev. 2000;34(3):119-36.10.1016/S0165-0173(00)00043-6]Search in Google Scholar